Compare AIRI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | TCRX |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 11.8M |
| IPO Year | 2013 | 2021 |
| Metric | AIRI | TCRX |
|---|---|---|
| Price | $2.65 | $0.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 34.4K | ★ 476.9K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.39 | 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,921,000.00 | $10,325,000.00 |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $2.30 | $0.17 |
| 52 Week High | $3.95 | $1.47 |
| Indicator | AIRI | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 31.96 |
| Support Level | $2.50 | N/A |
| Resistance Level | $2.75 | $0.21 |
| Average True Range (ATR) | 0.23 | 0.02 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 50.53 | 8.01 |
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.